SCHEMBL29993479

SCHEMBL29993479

O=C(O)CCn1nccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.47
EGLN3 Q9H6Z9 2/20 0.47
ESR1 P03372 1/20 0.42
KMO O15229 1/20 0.39
LMNA P02545 1/20 0.38
ALKBH5 Q6P6C2 1/20 0.38
SUCNR1 Q9BXA5 1/20 0.38
EGLN1 Q9GZT9 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TBXAS1 P24557 3/20 0.37
ALDH1A1 P00352 2/20 0.37
USP2 O75604 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
ALOX15 P16050 1/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22958943 0.86 LMNA (0.43) MAPK1EGLN3LMNASMN1; SMN2TBXAS1
SCHEMBL9022352 0.82 TBXAS1 (0.53) LMNATBXAS1ALDH1A1
SCHEMBL908783 0.74
SCHEMBL15330515 0.73 EGLN3 (0.46) MAPK1EGLN3ESR1KMOLMNA
Hydrochloric Acid SCHEMBL1372426 0.72 ALDH1A1 (0.41) MAPK1LMNAALDH1A1ALOX15
SCHEMBL4380616 0.67
SCHEMBL28396604 0.65
SCHEMBL11368195 0.65 EGLN3 (0.57) MAPK1EGLN3LMNAALKBH5SUCNR1
Succinic Acid SCHEMBL27814717 0.64 LMNA (0.60) MAPK1EGLN3LMNAALKBH5SUCNR1
Succinic Acid SCHEMBL4739951 0.61 LMNA (0.82) MAPK1LMNAALKBH5SUCNR1EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12233132-B2 Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same SERINA THERAPEUTICS, INC. (US) 2025-02-25 US disclosed
US-20240108750-A1 POLYOXAZOLINE-LIPID CONJUGATES AND LIPID NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME SERINA THERAPEUTICS, INC. (US) 2024-04-04 US disclosed
EP-4291242-A1 POLYOXAZOLINE-LIPID CONJUGATES AND LIPID NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME Serina Therapeutics, Inc. (US) 2023-12-20 EP disclosed
CN-117098558-A Polyoxazoline-lipid conjugates, lipid nanoparticles comprising same, and pharmaceutical compositions 塞瑞纳治疗公司 2023-11-21 CN disclosed
US-20220249695-A1 POLYOXAZOLINE-LIPID CONJUGATES AND LIPID NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME SERINA THERAPEUTICS, INC. (US) 2022-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12233132-B2 Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same RNMT, SPOP, PLIN5 MAPK1 4506/4885EGLN3 390/4885ESR1 4755/4885
US-20220249695-A1 POLYOXAZOLINE-LIPID CONJUGATES AND LIPID NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME RNMT, SPOP, PLIN5 MAPK1 4506/4885EGLN3 390/4885ESR1 4755/4885
US-20240108750-A1 POLYOXAZOLINE-LIPID CONJUGATES AND LIPID NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME RNMT, SPOP, PLIN5 MAPK1 4506/4885EGLN3 390/4885ESR1 4755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.